REGN Regeneron Pharmaceuticals, Inc.
Price Chart
Executive Summary
Regeneron announced that its Phase 3 trial of fianlimab (LAG-3 inhibitor) plus cemiplimab in first-line melanoma did not meet the primary endpoint of statistically significant improvement in progression-free survival (PFS) versus pembrolizumab monotherapy (p=0.0627). A numeric 5.1-month median PFS improvement was observed for the high-dose combination (11.5 vs 6.4 months), but the p-value missed the significance threshold. A head-to-head Phase 3 trial versus Opdualag is ongoing, but this miss reduces the probability of near-term regulatory filing and commercial upside for the combination.
Actionable Insight
Expect REGN to trade down 3-6% on this Phase 3 miss as the market prices out near-term regulatory filing probability. The ongoing Opdualag head-to-head trial remains a binary catalyst but now carries higher risk. Traders should watch for analyst downgrades and potential pipeline re-rating.
Key Facts
- Phase 3 trial of fianlimab + cemiplimab in first-line melanoma missed primary endpoint of PFS improvement vs pembrolizumab (p=0.0627).
- High-dose combination showed numeric 5.1-month median PFS improvement (11.5 vs 6.4 months) but did not reach statistical significance.
- Low-dose combination hazard ratio 0.931 (p=0.4661) — no signal of benefit.
- No new safety signals identified.
- A Phase 3 head-to-head trial versus Opdualag (nivolumab + relatlimab) is ongoing.
- Regeneron is a $74.7B market cap biotech with diversified pipeline, so this miss is significant but not existential.
Financial Impact
The miss delays or eliminates a potential $1B+ peak-sales opportunity in first-line melanoma. Regeneron's stock has historically underperformed on prior reports (avg T+20 alpha -12.70% vs SPY), and this negative catalyst may compound that trend.
Risk Factors
- Ongoing Phase 3 head-to-head trial versus Opdualag could also fail, further impairing fianlimab's value.
- Competitive landscape: Opdualag (BMS) already approved in first-line melanoma; Keytruda (Merck) is standard of care.
- Regeneron's historical T+20 performance on prior reports is poor (avg alpha -12.70%), suggesting the stock may already be under structural pressure.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296192 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
May 21, 2026
19d ago
|
Press Release
| $638.53 $600.65 | ▼ −5.93% | ▼ −7.59% | $611.34 (−4.26%) |
|
May 18, 2026
22d ago
|
ANALYST-DOWNGRADE
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 18, 2026
22d ago
|
Press Release
| $629.34 $632.17 | ▲ +0.45% | ▼ −1.17% | $611.34 (−2.86%) |
|
May 16, 2026
25d ago
|
Press Release
| $629.34 $632.17 | ▼ −0.45% | ▲ +1.17% | $611.34 (+2.86%) |
|
May 15, 2026
25d ago
|
Press Release
| $696.20 $638.53 | ▼ −8.28% | ▼ −9.25% | $611.34 (−12.19%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $810.25 $752.29 | ▼ −7.15% | ▼ −7.28% | $611.34 (−24.55%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $744.35 $709.19 | ▼ −4.72% | ▼ −5.12% | $611.34 (−17.87%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $747.15 $729.36 | ▼ −2.38% | ▼ −3.46% | $611.34 (−18.18%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $745.61 $749.26 | ▲ +0.49% | ▼ −2.81% | $611.34 (−18.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access